In vitro measurements of metabolism for application in pharmacokinetic modeling

Pharmacology and Therapeutics

Volumn 118, Issue 1, 2008, Pages 82-103

  Lipscomb, John C ^a   Poet, Torka S ^b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Drug metabolism; Genetic polymorphisms; In vitro to in vivo extrapolation; Interspecies extrapolation; Physiologically based pharmacokinetic modeling; Risk assessment

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BENZODIAZEPINE DERIVATIVE; CELL PROTEIN; CHLOROFORM; CLARITHROMYCIN; CYTOCHROME P450; DIMETHYLANILINE MONOOXYGENASE; DIMPYLATE; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FLUCONAZOLE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HYDROQUINONE; KETOCONAZOLE; MIDAZOLAM; NEVIRAPINE; RECOMBINANT ENZYME; TETRACHLOROETHYLENE; TRICHLOROETHYLENE;

ALLOMETRY; AREA UNDER THE CURVE; CATALYSIS; CELL FRACTIONATION; CELL ISOLATION; CYTOSOL; DRUG BINDING; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RESEARCH; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; LIVER BLOOD FLOW; LIVER CELL; LIVER CLEARANCE; LIVER HOMOGENATE; LIVER METABOLISM; LYMPHOBLASTOID CELL; METABOLIC RATE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SLICE; TOXICOKINETICS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SPECIES SPECIFICITY;

EID: 42649085362     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.01.006     Document Type: Review

References (117)

1. Allen B.C., and Fisher J.W. Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. Risk Anal 13 (1993) 71-86
2. Andersen M.E. Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol Lett 138 (2003) 9-27
3. Andersen M.E., and Krishnan K. Physiologically based pharmacokinetics and cancer risk assessment. Environ Health Perspect 102 Suppl 1 (1994) 103-108
4. In: Arias I.M., Popper H., Schachter D., and Shafritz D.A. (Eds). The Liver: Biology and Pathobiology (1982), Raven Press, New York, NY
5. Bachmann K.A. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug-drug interactions: pitfalls, progress and promise. Curr Drug Metab 7 (2006) 1-14
6. Baranczewski P., Stanczak A., Sundberg K., Svensson R., Wallin A., Jansson J., et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58 (2006) 453-472
7. Barter Z.E., Bayliss M.K., Beaune P.H., Boobis A.R., Carlile D.J., Edwards R.J., et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8 (2007) 33-45
8. Billings R.E., McMahon R.E., Ashmore J., and Wagle S.R. The metabolism of drugs in isolated rat hepatocytes. A comparison with in vivo drug metabolism and drug metabolism in subcellular liver fractions. Drug Metab Dispos 5 (1977) 518-526
9. Bois F.Y. Analysis of PBPK models for risk characterization. Ann NY Acad Sci 895 (1999) 317-337
10. Brightman F.A., Leahy D.E., Searle G.E., and Thomas S. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab Dispos 34 (2006) 94-101
11. Brown S.E., Guzelian C.P., Schuetz E., Quattrochi L.C., Kleinman H.K., and Guzelian P.S. Critical role of extracellular matrix on induction by phenobarbital of cytochrome P450 2B1/2 in primary cultures of adult rat hepatocytes. Lab Invest 73 (1995) 818-827
12. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13 (1997) 407-484
13. Brown H.S., Griffin M., and Houston J.B. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35 (2007) 293-301
14. Carlile D.J., Zomorodi K., and Houston J.B. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab Dispos 25 (1997) 903-911
15. Chiu W.A., Barton H.A., DeWoskin R.S., Schlosser P., Thompson C.M., Sonawane B., et al. Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J Appl Toxicol 27 (2007) 218-237
16. Clewell H.J., Gentry P.R., Covington T.R., Sarangapani R., and Teeguarden J.G. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 79 (2004) 381-393
17. Corley R.A., Mendrala A.L., Smith F.A., Staats D.A., Gargas M.L., Conolly R.B., et al. Development of a physiologically based pharmacokinetic model for chloroform. Toxicol Appl Pharmacol 103 (1990) 512-527
18. Corley R.A., English J.C., Hill T.S., Fiorica L.A., and Margott D.A. Development of a physiologically based pharmacokinetic model for hydroquinone. Toxicol Appl Pharmacol 165 (2000) 163-174
19. Corley R.A., Mast T.J., Carney E.W., Rogers J.M., and Daston G.P. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit Rev Toxicol 33 (2003) 137-211
20. Crespi C.L., and Penman B.W. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 43 (1997) 171-188
21. Crespi C.L., Steimel D.T., Penman B.W., Korzekwa K.R., Fernandez-Salguero P., Buters J.T., et al. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics 5 (1995) 234-243
22. Daus L., Meinke M., and Calvin M. Propionic acid metabolism in mouse liver slices. J Biol Chem 196 (1952) 77-87
23. Dickinson D.A., and Forman H.J. Glutathione in defense and signaling: lessons from a small thiol. Ann NY Acad Sci 973 (2002) 488-504
24. Ding X.X., and Kaminsky L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Ann Rev Pharmacol Toxicol 43 (2003) 149-173
25. Doherty M.M., and Pang K.S. First-pass effect: significance of the intestine for absorption and metabolism. Drug Chem Toxicol 20 (1997) 329-344
26. Forman H.J., and Dickinson D.A. Oxidative signaling and glutathione synthesis. Biofactors 17 (2003) 1-12
27. Gardner I., Wakazono H., Bergin P., deWaziers I., Beaune P., Kenna J.G., et al. Cytochrome P450 mediated bioactivation of methylglyoxal to 1′-hydroxymethyleugenol in Fischer 344 rat and human liver microsomes. Carcinogenesis 18 (1997) 1775-1783
28. Gentry P.R., Hack C.E., Haber L., Maier A., and Clewell H.J. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol Sci 70 (2002) 120-139
29. Germain E., Chevalier J., Siess M.H., and Teyssier C. Hepatic metabolism of diallyl disulphide in rat and man. Xenobiotica 33 (2003) 1185-1199
30. Giuliano C., Jairaj M., Zafiu C.M., and Laufer R. Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab Dispos 33 (2005) 1319-1324
31. Griffin S.J., and Houston J.B. Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metab Dispos 32 (2004) 552-558
32. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 27 (1999) 922-935
33. Grime K., and Riley R.J. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 7 3 (2006) 251-264
34. Guengerich F.P. Analysis and characterization of enzymes. In: Hayes A.W. (Ed). Principles and Methods of Toxicology (1994), Raven Press Ltd, New York, NY
35. Haber L.T., Maier A., Gentry P.R., Clewell H.J., and Dourson M.L. Genetic polymorphisms in assessing interindividual variability in delivered dose. Regul Toxicol Pharmacol 35 (2002) 177-197
36. Harris J.W., Rahman A., Kim B.R., Guengerich F.P., and Collins J.M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54 (1994) 4026-4035
37. Hein D.W. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25 (2006) 1649-1658
38. Hein D.W., Fretland A.J., and Doll M.A. Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int J Cancer 119 (2006) 1208-1211
39. Hengstler J.G., Utesch D., Steinberg P., Platt K., Diener B., Ringel M., et al. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Dispos 32 (2000) 81-118
40. Hewitt N.J., Lechon M.J., Houston J.B., Hallifax D., Brown H.S., Maurel P., et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39 (2007) 159-234
41. Hilderbrand R.L., Andersen M.E., and Jenkins Jr. L.J. Prediction of in vivo kinetic constants for metabolism of inhaled vapors from kinetic constants measured in vitro. Fundam Appl Toxicol 1 (1981) 403-409
42. Hill B.A., Davison K.L., Dulik D.M., Monks T.J., and Lau S.S. Metabolism of 2-(glutathion-S-yl)hydroquinone and 2,3,5-(triglutathion-S-yl)hydroquinone in the in situ perfused rat kidney: relationship to nephrotoxicity. Toxicol Appl Pharm 129 (1994) 121-132
43. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47 (1994) 1469-1479
44. Houston J.B., and Carlile D.J. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29 (1997) 891-922
45. Houston J.B., and Kenworthy K.E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28 (2000) 246-254
46. IPCS (International Programme on Chemical Safety). Chemical-specific adjustment factors for interspecies differences and human variability: guidance document for use of data in dose/concentration-response assessment. Harmonization Project Document No. 2. (2005), World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland
47. Ito K., Ogihara K., Kanamitsu S., and Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31 (2003) 945-954
48. Johnson T.N., Tucker G.T., Tanner M.S., and Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 12 11 (2005) 1481-1493
49. Kedderis G.L. In vitro to in vivo extrapolation of metabolic rate constants for physiologically based pharmacokinetic models. In: Lipscomb J.C., and Ohanian E.V. (Eds). Toxicokinetics and Risk Assessment (2007), Informa Healthcare USA, Inc, New York, NY
50. Kedderis G.L., and Held S.D. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol Appl Pharm 140 (1996) 124-130
51. Kedderis G.L., and Lipscomb J.C. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment. Toxicol Ind Health 17 (2001) 315-321
52. Kedderis G.L., Carfagna M.A., Held S.D., Batra R., Murphy J.E., and Gargas M.L. Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. Toxicol Appl Pharm 123 (1993) 274-282
53. Kenworthy K.E., Bloomer J.C., Clarke S.E., and Houston J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48 (1999) 716-727
54. Kirman C.R., Sweeney L.M., Meek M.E., and Gargas M.L. Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. Regul Toxicol Pharmacol 38 3 (2003) 345-367
55. Kishimoto W., Takano J., Senda C., Ishiguro N., Sakai K., and Igarashi T. Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. Biol Pharm Bull 23 (2000) 1027-1032
56. In: Klaassen C.D. (Ed). Casarett & Doull's Toxicology: The Basic Science of Poisons. 6th Edition (2001), McGraw-Hill, New York, NY
57. Kocarek T.A., Schuetz E.G., and Guzelian P.S. Expression of multiple forms of cytochrome P450 mRNAs in primary cultures of rat hepatocytes maintained on matrigel. Mol Pharmacol 43 (1993) 328-334
58. Krishnan K., and Johanson G. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment. J Environ Sci Health C 23 (2005) 31-53
59. Lave T., and Coassolo P. Commentary on "Integration of in vitro data and brain weight in allometric scaling to predict clearance in humans: some suggestions.". J Pharm Sci 87 4 (1998) 530
60. Li A.P., Lu C., Brent J.A., Pham C., Fackett A., Ruegg C.E., et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem-Biol Interact 121 (1999) 17-35
61. Li D., Jiao L., Li Y., Doll M.A., Hein D.W., Bondy M.L., et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 27 (2006) 103-111
62. Lin J.H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26 12 (1998) 1202-1212
63. Lin J.H. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharmacol Res 23 (2006) 1089-1116
64. Lin J.H., Chiba M., and Baillie T.A. Is the role of the small intestine in first-pass metabolism overemphasized?. Pharmacol Rev 51 (1999) 135-157
65. Lipscomb J.C., Garrett C.M., and Snawder J.E. Cytochrome P450-dependent metabolism of trichloroethylene: interindividual differences in humans. Toxicol Appl Pharm 142 (1997) 311-318
66. Lipscomb J.C., Fisher J.W., Confer P.D., and Byczkowski J.Z. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. Toxicol Appl Pharm 152 (1998) 376-387
67. Lipscomb J.C., Teuschler L.K., Swartout J., Popken D., Cox T., and Kedderis G.L. The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal 23 (2003) 1221-1238
68. Lipscomb J.C., Teuschler L.K., Swartout J.C., Striley C.A.F., and Snawder J.E. Variance of microsomal protein and cytochrome P450 2E1 and 3A forms in adult human liver. Toxicol Mech Method 13 (2003) 45-51
69. Lipscomb J.C., Meek M.E., Krishnan K., Kedderis G.L., Clewell H., and Haber L. Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments. Toxicol Mech Method 14 (2004) 145-158
70. Lipscomb J.C., Barton H., Tornero-Velez R., Evans M.V., Alcasey S., Snawder J.E., et al. The metabolic rate constants and specific activity of human and rat cytochrome P450 2E1 toward chloroform. J Toxicol Environ Health A 67 (2004) 537-553
71. Liu L., and Pang K.S. An integrated approach to model hepatic drug clearance. Eur J Pharm Sci 29 (2006) 215-230
72. Mahmood I. Integration of in vitro data and brain weight in allometric scaling to predict clearance in humans: some suggestions. J Pharm Sci 87 (1998) 527-529
73. Mahmood I. Interspecies scaling: predicting oral clearance in humans. Am J Ther 9 (2002) 35-42
74. McGinnity D.F., Soars M.G., Urbanowicz R.A., and Riley R.J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32 (2004) 1247-1253
75. Nagilla R., Frank K.A., Jolivette L.J., and Ward K.W. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J Pharmacol Toxicol 53 (2006) 106-116
76. Nakajima M., Nakamura S., Tokudome S., Shimada N., Yamazaki H., and Yokoi T. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27 (1999) 1381-1391
77. Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A., and Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29 (2001) 1316-1324
78. Naritomi Y., Terashita S., Kagayama A., and Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31 (2003) 580-588
79. Obach R.S. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro in vivo correlations. Drug Metab Dispos 24 (1996) 1047-1049
80. Obach R.S. The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Dev 4 (2001) 36-44
81. Obach R.S., Zhang Q.Y., Dunbar D., and Kaminsky L.S. Metabolic characterization of the major human small intestinal cytochrome P450s. Drug Metab Dispos 29 (2001) 347-352
82. Obach R.S., Walsky R.L., Venkatakrishnan K., Gaman E.A., Houston J.B., and Tremaine L.M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316 (2006) 336-348
83. Pelkonen O., Kaltiala E.H., Larmi T.K., and Karki N.T. Comparison of activities of drug-metabolizing enzymes in human fetal and adult livers. Clin Pharmacol Ther 14 (1973) 840-846
84. Plowchalk D.R., and Teeguarden J. Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: a biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. Toxicol Sci 69 (2002) 60-78
85. Poet T.S., Brendel K., and Halpert J.R. Inactivation of cytochromes P450 2B protects against cocaine-mediated toxicity in rat liver slices. Toxicol Appl Pharmacol 126 (1994) 26-32
86. Poet T.S., Wu H., Kousba A.A., and Timchalk C. In vitro rat hepatic and intestinal metabolism of the organophosphate pesticides chlorpyrifos and diazinon. Toxicol Sci 72 2 (2003) 193-200
87. Poet T.S., Wu H., English J.C., and Corley R.A. Metabolic rate constants for hydroquinone in F344 rat and human liver isolated hepatocytes: application to a PBPK model. Toxicol Sci 82 (2004) 9-25
88. Poet T.S., Kousba A.A., Dennison S.L., and Timchalk C. Physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus pesticide diazinon. Neurotoxicology 25 6 (2004) 1013-1030
89. Pond A.L., Chambers H.W., and Chambers J.E. Organophosphate detoxication potential of various rat tissues via A-esterase and aliesterase activities. Toxicol Lett 78 (1995) 245-252
90. Proctor N.J., Tucker G.T., and Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34 (2004) 151-178
91. Rane A., Wilkinson G.R., and Shand D.G. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 200 (1977) 420-424
92. Rawden H.C., Carlile D.J., Tindall A., Hallifax D., Galetin A., Ito K., et al. Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica 35 (2005) 603-625
93. Reitz R.H., Gargas M.L., Mendrala A.L., and Schumann A.M. In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokinetic modeling in rats, mice, and humans. Toxicol Appl Pharmacol 136 (1996) 289-306
94. Remmel R.P., and Burchell B. Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem Pharmacol 46 (1993) 559-566
95. Sanwald-Ducray P., and Dow J. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. Xenobiotica 27 (1997) 189-201
96. Schneider K., Oltmanns J., and Hassauer M. Allometric principles for interspecies extrapolation in toxicological risk assessment-empirical investigations. Regul Toxicol Pharmacol 39 3 (2004) 334-347
97. Schuetz E.G., Schuetz J.D., Strom S.C., Thompson M.T., Fisher R.A., Molowa D.T., et al. Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18 (1993) 1254-1262
98. Seglen P.O. Preparation of isolated rat liver cells. Method Cell Biol 13 (1976) 29-83
99. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
100. Shimada T., Yamazaki H., Mimura M., Wakamiya N., Ueng Y.F., Guengerich F.P., et al. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs. Drug Metab Dispos 24 (1996) 515-522
101. Skaggs S.M., Foti R.S., and Fisher M.B. A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma. J Pharmacol Toxicol Methods 53 (2006) 284-290
102. Snawder J.E., and Lipscomb J.C. Interindividual variance of cytochrome P450 forms in human hepatic microsomes: correlation of individual forms with xenobiotic metabolism and implications in risk assessment. Regul Toxicol Pharm 32 (2000) 200-209
103. 3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes. Xenobiotica 37 (2007) 832-854
104. Stormer E., von Moltke L.L., and Greenblatt D.J. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J Pharmacol Exp Ther 295 (2000) 793-801
105. Sultatos L.G. Mammalian toxicology of organophosphorus pesticides. J Toxicol Environ Health 43 (1994) 271-289
106. Sutter T.R. Molecular and cellular approaches to extrapolation for risk assessment. Environ Health Perspect 103 (1995) 386-389
107. Tang H., and Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33 (2005) 1297-1303
108. Thrall K.D., Vucelick M.E., Gies R.A., Zangar R.C., Weitz K.K., Poet T.S., et al. Comparative metabolism of carbon tetrachloride in rats, mice, and hamsters using gas uptake and PBPK modeling. J Toxicol Environ Health A 60 (2000) 531-548
109. Timchalk C., Kousba A., and Poet T. Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. Toxicol Lett 135 (2002) 51-59
110. Transon C., Lecoeur S., Leemann T., Beaune P., and Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol 51 (1996) 79-85
111. Treijtel N., Barendregt A., Freidig A.P., Blaauboer B.J., and van Eijkeren J.C. Modeling the in vitro intrinsic clearance of the slowly metabolized compound tolbutamide determined in sandwich-cultured rat hepatocytes. Drug Metab Dispos 32 (2004) 884-891
112. U.S. EPA (Environmental Protection Agency). (2005). Use of Physiologically Based Pharmacokinetic Models to Quantify the Impact of Human Age and Interindividual Differences in Physiology and Biochemistry Pertinent to Risk: Final Report for Cooperative Agreement, Lipscomb, J.C. & Kedderis, G.L. (Eds.). Cincinnati, OH: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment. EPA/600/R-06/014A.
113. Venkatakrishnan K., von Moltke L.L., Court M.H., Harmatz J.S., Crespi C.L., and Greenblatt D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28 (2000) 1493-1504
114. Worboys P.D., Bradbury A., and Houston J.B. Kinetics of drug-metabolism in rat-liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high-clearance and low-clearance compounds. Drug Metab Dispos 23 (1995) 393-397
115. Yang R.S., el Masri H.A., Thomas R.S., Constan A.A., and Tessari J.D. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures. Toxicol Lett 79 (1995) 193-200
116. Yoon M., Madden M.C., and Barton H.A. Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: impacts on metabolic parameter estimation and prediction of dose metrics. J Toxicol Environ Health A 70 (2007) 1527-1541
117. Zhang X., Lambert J.C., Doll M.A., Walraven J.M., Arteel G.E., and Hein D.W. 4,4′-methylenedianiline-induced hepatotoxicity is modified by N-acetyltransferase 2 (NAT2) acetylator polymorphism in the rat. J Pharmacol Exp Ther 316 (2006) 289-294